Hims & Hers Semaglutide Pill Undercuts Wegovy Price
Hims & Hers Semaglutide Pill launch introduced a lower-cost compounded semaglutide option and prompted HIMS stock swings while pressuring other GLP peers.
KEY TAKEAWAYS
- Launched a compounded semaglutide pill as a lower-cost oral alternative to Wegovy on Feb. 5, 2026.
- Introductory pricing started at $49 first month with a five-month plan then $99 per month.
- Company noted compounded drugs are not FDA-approved and said APIs come from FDA-registered facilities.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Hims & Hers Health, Inc. (NYSE: HIMS) launched a compounded semaglutide pill on Feb. 5, 2026, offering an oral alternative to Wegovy that expands lower-cost, online-prescribed weight-loss options. The announcement prompted near-term stock moves in HIMS, while shares of Novo Nordisk and Eli Lilly declined.
Product Pricing, Access, and Infrastructure
The company expanded its weight-loss offerings with a compounded semaglutide pill, an oral once-daily formulation using the same active ingredient as Wegovy. The pill is designed to protect the compound during digestion to support absorption. Hims & Hers said this option allows providers to tailor treatment for patients who prefer to avoid injections or require smaller doses to manage side effects.
Introductory pricing is $49 for the first month under a five-month upfront plan, with a recurring price of $99 per month thereafter. The product is available by provider prescription following an online consultation and is offered as part of the company’s holistic weight-loss plans.
To support compounding operations, Hims & Hers doubled its facility footprint in 2025 to more than 1 million square feet, expanding pharmacy, lab-testing, and research and development capacity.
Regulatory Standards and Market Reaction
Hims & Hers noted that compounded drug products are not approved by the FDA. The company said its active pharmaceutical ingredients will be sourced from FDA-registered facilities, and compounding will comply with federal and state standards.
The announcement coincided with near-term market moves: HIMS stock rose while shares of Novo Nordisk and Eli Lilly declined over the past 72 hours.
"Our goal at Hims & Hers is simple: better outcomes through better access," the company said.
